Stay updated on Durvalumab Combo in Resectable NSCLC Clinical Trial
Sign up to get notified when there's something new on the Durvalumab Combo in Resectable NSCLC Clinical Trial page.

Latest updates to the Durvalumab Combo in Resectable NSCLC Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe history now includes a new Revision: v3.4.2 entry, and the prior government funding notice and Revision: v3.4.1 entry were removed. These changes relate to page versioning and site notices rather than the trial data or study details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.6%

- Check21 days agoChange DetectedAdded a site-wide notice about government funding and the page revision tag v3.4.1, replacing v3.4.0; no study data, eligibility, or results were affected. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.6%

- Check28 days agoChange DetectedThe history page now includes a glossary toggle and displays change highlights using green for additions and red for deletions, along with an updated revision label. No core study content, results, or critical details were modified; to avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.8%

- Check42 days agoChange DetectedThe page history now shows a new revision entry (v3.3.4) and the previous revision (v3.3.3) has been removed, reflecting a minor update to the record history. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check64 days agoChange DetectedRevision: v3.3.3 was added. HHS Vulnerability Disclosure and Revision: v3.3.2 were removed.SummaryDifference0.2%

- Check85 days agoChange DetectedRevision label on the header updated from v3.3.1 to v3.3.2.SummaryDifference0.1%

Stay in the know with updates to Durvalumab Combo in Resectable NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab Combo in Resectable NSCLC Clinical Trial page.